Clinically relevant outcome measures of novel pharmacotherapy for nonallergic rhinitis

  title={Clinically relevant outcome measures of novel pharmacotherapy for nonallergic rhinitis},
  author={Kari R. Brown and Jonathan A. Bernstein},
  journal={Current Opinion in Allergy and Clinical Immunology},
  • K. Brown, J. Bernstein
  • Published 1 June 2015
  • Medicine
  • Current Opinion in Allergy and Clinical Immunology
Purpose of reviewThe purpose of this review is to briefly provide the current understanding of the pathogenesis of nonallergic rhinitis (NAR), currently available pharmacotherapies as well as some recent advancement in pharmacotherapy for this condition. With this background on NAR, we then describe and contrast outcome measures used in previous NAR and allergic rhinitis clinical trials. Finally, we conclude with a brief discussion on which of these outcomes might be most suitable for future… 
Effect of Intranasal Corticosteroids on Secondary Sinonasal Symptoms: A Systematic Review of Randomized Trials
Limited data are available regarding the effectiveness of aqueous or nonaqueous INCS on secondary symptoms in adult patients with rhinitis, and further study is needed using homogenous outcome measures and direct comparison of INCS formulations.
Non-Allergic Rhinitis
Combination of intranasal fluticasone propionate together with azelatine has recently proved to be better than corticosteroid alone for the treatment of chronic rhinitis, both allergic and non-allergic.
Prevalence, comorbidities, diagnosis, and treatment of nonallergic rhinitis: real-world comparison with allergic rhinitis
The prevalence, diagnosis, comorbidities, and treatment recommendations for nonallergic rhinitis versus allergic Rhinitis in children is reviewed.
By the numbers: bringing new drugs for allergic/hypersensitivity diseases to the market.
DOI:10.1097/ACI.0000000000000170 clinical presentations, including asthma, rhinitis, anaphylaxis, drug, food, and insect hypersensitivity, eczema, urticaria and angioedema. The impact of
A pilot study to determine the effects of nasal co-phenylcaine on drug-induced sleep endoscopy
A pilot study supports the use of co-phenylcaine nasal spray during DISE and the positive effects of the nasal spray do not influence the grading outcome, while the nasal anaesthetic component may be beneficial by reducing nasal discomfort duringDISE and thereby helping to reduce the total dose of intravenous anaesthetic administered.


Nonallergic rhinitis: therapeutic options
  • J. Bernstein
  • Medicine
    Current opinion in allergy and clinical immunology
  • 2013
Methods for classifying Nonallergic rhinitis (NAR), the current understanding of its immunopathogenesis, scientific evidence-based treatment options along with anecdotal clinical experience for selecting different treatment regimens for these challenging patients are discussed.
Treatment of nonallergic perennial rhinitis
Azelastine nasal spray may be considered as primary therapy for patients with symptoms of both allergic and/or vasomotor (nonallergic perennial) rhinitis, since azelASTine has a more rapid onset of action, compared to most other antihistamines and intranasal corticosteroids.
MP29-02: a breakthrough for the treatment of allergic rhinitis
The goal of this article is to review all MP29-02 clinical data currently published with a view to establish its potential to fill the current unmet medical need in AR.
Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis
MP29-02 provided faster and more complete symptom control than first-line therapies and may be considered the drug of choice for moderate-to-severe AR, and defines a new standard for assessing relevance in AR.
Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia.
  • D. Webb, E. Meltzer, +4 authors C. K. Cook
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2002
Intranasal FP is an effective treatment for perennial nonallergic rhinitis with or without nasal eosinophilia (NARes or non-NARES), and means change in total nasal symptom score (TNSS), a sum of patient ratings of nasal obstruction, postnasal drip, and rhinorrhea.
Intranasal Flunisolide Treatment in Patients with Non-Allergic Rhinitis
Intranasal flunisolide induced a significant reduction of symptoms, turbinate size, and cellular infiltrate in patients with non-allergic rhinitis, suggesting it might be a therapeutic option for NAR.
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR and was observed from the first day of assessment, with improvement in each individual nasal symptom, even in the patients with the most severe disease.
Thoughts on the pathophysiology of nonallergic rhinitis
  • W. Fokkens
  • Medicine
    Current allergy and asthma reports
  • 2002
A careful determination of the intensity of the symptoms combined with modern diagnostic tools enables us to discriminate idiopathic rhinitis patients from normal controls, and discusses the possible pathophysicologic mechanisms of nonallergic noninfectious rhineitis.
A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
Results confirm MP29-02's wide therapeutic spectrum and assert its consistent superiority over an intranasal corticosteroid in patients with chronic rhinitis.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis.
The addition of oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis, and the need for a large multicenter study to develop a once-a-day combination of an intranasal steroid and a long-acting topical decongestant is suggested.